Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals.
This study sought to quantitate the response of late complement component-deficient (LCCD) individuals to the meningococcal vaccine, to examine antibody persistence, and to investigate the contribution of these antibodies to meningococcal killing in complement- and phagocyte-dependent bactericidal assays. The mean concentration of antibody to group A and C capsular polysaccharide after vaccination was similar in 8 LCCD, 11 family members, and 7 unrelated normal individuals. LCCD individuals had a greater percentage decline in antibody concentration to group C polysaccharide and had lower concentrations of antibody to group Y polysaccharide 2.0-2.5 years after vaccination than did normal and heterozygous deficient persons. Antibody to subcapsular antigens was minimally effective in mediating complement-dependent killing and had no effect in the opsonophagocytic assay. In contrast, antibody to capsular polysaccharide promoted meningococcal killing in both assays. These data support vaccination as a preventive measure in LCCD individuals and lend credence to the idea that these individuals are critically dependent on capsular antibody for protection against meningococcal disease.
Department of Internal Medicine, VA Medical Center, Iowa City.
J
J
Andreoni
H
H
Käyhty
P
P
Densen
D000328:Adult; D000907:Antibodies, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D003184:Complement C7 / Q000172:deficiency*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000276:immunology; D008297:Male; D008589:Meningococcal Infections / Q000150:complications / Q000517:prevention & control*; D011134:Polysaccharides / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D003184:Complement C7; D011134:Polysaccharides